Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial-Reference-Cited by-同舟云学术

Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial

Published:2021-11-24 Issue: Volume: Page:
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Abu‐Ghanem Yasmin¹^ORCID,Thienen Johannes V.²,Blank Christian²,Aarts Maureen J. B.³,Jewett Michael⁴,Jong Igle Jan⁵,Lattouf Jean‐Baptiste⁶,Melick Harm H. E.⁷,Wood Lori⁸,Mulders Peter⁹,Rottey Sylvie¹⁰,Wagstaff John¹¹,Zondervan Patricia¹²,Powles Tom¹³,Neven Anouk¹⁴,Collette Laurence¹⁴,Tombal Bertrand¹⁴¹⁵^ORCID,Haanen John²,Bex Axel¹²

Affiliation:

1. Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science London UK

2. Netherlands Cancer Institute Amsterdamthe Netherlands

3. Maastricht University Medical Center Maastricht the Netherlands

4. Princess Margaret Hospital Toronto ON Canada

5. University of Groningen University Medical Center Groningen the Netherlands

6. University of Montreal Hospital Center Montreal QC Canada

7. Saint Antonius Hospital Nieuwegein the Netherlands

8. QEII Health Sciences Center Halifax NS Canada

9. Radboud University Hospital Nijmegen the Netherlands

10. Ghent University Hospital GhentUK

11. South West Wales Cancer Centre and Swansea University College of Medicine Swansea UK

12. University Medical Centers Amsterdam the Netherlands

13. Barts and Queen Mary University London London UK

14. European Organisation of Research and Treatment of Cancer (EORTC) Brussels Belgium

15. Cliniques Universitaires Saint‐Luc Brussels Belgium

Funder

Pfizer

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bju.15625

Reference21 articles.

1. Cancer statistics, 2009;Jemal A;CA Cancer J Clin,2009

2. Surveillance strategies for renal cell carcinoma patients following nephrectomy;Chin AI;Rev Urol,2006

3. Radical nephrectomy plus interferon‐alfa‐based immunotherapy compared with interferon alfa alone in metastatic renal‐cell carcinoma: A randomised trial;Mickisch GH;Lancet,2001

4. Nephrectomy followed by interferon alfa‐2b compared with interferon alfa‐2b alone for metastatic renal‐cell cancer;Flanigan RC;N Engl J Med,2001

5. Sunitinib alone or after nephrectomy in metastatic renal‐cell carcinoma;Méjean A;N Engl J Med,2018

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review;Future Oncology;2024-09-11

2. Cytoreductive nephrectomy in metastatic renal cell carcinoma;Cochrane Database of Systematic Reviews;2024-06-07

3. Role of Surgery in Metastatic Renal Cell Carcinoma;Hematology/Oncology Clinics of North America;2023-10

4. Comparison of upfront versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving systemic therapy: A systematic review and meta-analysis;International Journal of Surgery;2023-07-17

5. Integrating Surgery in the Multidisciplinary Care of Advanced Renal Cell Carcinoma;Urologic Clinics of North America;2023-05